Megan Hollasch

Articles

Considering the Data Behind Belzutifan's Approval in VHL Disease–Associated Cancers

November 10th 2023

Jaleh Fallah, MD, discusses the FDA's evaluation of data from the phase 2 LITESPARK-004 trial, which supported the approval of belzutifan in von Hippel-Lindau–associated cancers.

Markman Underscores Unanswered Questions in Ovarian Cancer Management

November 9th 2023

Although advancements were “simple” to track for more than 40 years and left few questions open for evaluation in the ovarian cancer treatment paradigm, new questions have begun to develop surrounding the complexity of care.

Lamanna Details Evolution of CLL Treatment Following Resistance

November 9th 2023

Nicole Lamanna, MD, discusses treatment options for patients with chronic lymphocytic leukemia who develop resistance to a prior treatment.

Investigators Deliver Updates on Evolving Clinical Trials Evaluating ADCs in Lung Cancer

November 2nd 2023

Melissa L. Johnson, MD, Terufumi Kato, MD, and Pasi A. Jänne, MD, PhD, present updates from the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer.

Novel B7-H4 Targeted ADCs Generate Activity and Show Manageable Safety Profile in Breast and Other Cancers

October 31st 2023

Two novel antibody-drug conjugates, HS-20089 and SGN-B7H4V, targeting the highly expressed immune checkpoint ligand B7-H4 have demonstrated manageable safety profiles and shown anti-tumor activity in first-in-human dose-escalation portions of phase 1 trials and will move forward to the next portions of the studies.

ImPrint Biomarker Predicts Immunotherapy Response in Patients With HR+/HER2– Breast Cancer

October 25th 2023

Denise M. Wolf, PhD, discusses the methods used to conduct the I-SPY2 study and the implications that immune biomarkers could have on selecting treatment for patients with hormone receptor–positive, HER2-negative breast cancer in the future.

Updated Data Continue to Aid IO-Based Frontline Treatment Decisions in Advanced RCC

October 24th 2023

Tian Zhang, MD, MHS, details how updated data presented at the 2023 ASCO Annual Meeting from trials such as KEYNOTE-426 and CLEAR have showed the sustained efficacy of VEGF plus immunotherapy combinations vs sunitinib in the first-line setting; discusses where the immunotherapy-only combination of ipilimumab and nivolumab fits in the frontline setting; and highlights how data from CONTACT-03 provided key insights on the use of immunotherapy in patients with advanced renal cell carcinoma after progression on a prior immune checkpoint inhibitor.

Dato-DXd Significantly Improves PFS in Select Subsets of Advanced/Metastatic NSCLC

October 23rd 2023

The Trop-2 directed antibody drug conjugate datopotamab deruxtecan demonstrated a statistically significant improvement in progression-free survival vs docetaxel in patients with advanced or metastatic non–small cell lung cancer, however those with squamous histology did not experience a benefit.

Etigilimab Plus Nivolumab Shows Activity in Recurrent/Advanced Solid Tumors, and Possible Biomarkers Emerge

October 21st 2023

Combination treatment with etigilimab and nivolumab was well tolerated in patients with recurrent or advanced solid tumors and promising efficacy was seen for patients with PD-L1 low disease

Pembrolizumab Plus Chemoradiotherapy Shows Statistically Significant PFS Benefit vs SOC in High-Risk Locally Advanced Cervical Cancer

October 20th 2023

The addition of pembrolizumab to external beam radiotherapy and concurrent chemotherapy, followed by brachytherapy, resulted in statistically significant and clinically meaningful improvements in progression-free survival when compared with placebo plus EBRT/chemoradiotherapy/brachytherapy in patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer.

Next-Generation Aniten Masofaniten Gains Momentum in mCRPC

October 18th 2023

The emergence of a novel class of compounds, known as anitens, potentially offers clinicians the ability to elongate responses for patients with metastatic castration-resistant prostate cancer, with the first-in-class N-terminal domain androgen receptor inhibitor masofaniten showing promise as it moves to the phase 2 portion of a phase 1/2 trial.

DLL3-Targeting Agents Are Poised to Fill Unmet Needs in SCLC

October 18th 2023

Expression of DLL3, an inhibitor ligand of the Notch pathway associated with tumorigenesis, has emerged as a target of interest for drug development.

Pirtobrutinib to be Compared with Ibrutinib in CLL/SLL Ongoing BRUIN CLL-314 Trial

October 13th 2023

The phase 3 BRUIN CLL-314 trial evaluating the selective noncovalent BTK inhibitor pirtobrutinib vs the potent covalent BTK inhibitor ibrutinib is currently enrolling patients with chronic lymphocytic leukemia and small lymphocytic lymphoma who previously received treatment with non-BTK inhibitor therapy.

Dual Inhibition With Bezuclastinib/Sunitinib Aims to Fill an Unmet Need in GIST

October 10th 2023

Combination therapy targeting multiple exons where mutations commonly develop in gastrointestinal stromal tumor may represent a promising treatment approach to increase efficacy when patients develop resistance to therapies such as imatinib.

Venetoclax/Carfilzomib/Dexamethasone Triplet Shows Early Efficacy in t(11;14)+ R/R Myeloma

September 30th 2023

The addition of venetoclax to carfilzomib and dexamethasone increased response rates compared with carfilzomib plus dexamethasone alone in patients with t(11:14)-positive relapsed/refractory multiple myeloma.

BASECAMP-1 Trial Selects Patients With Solid Tumors for Future Treatment With Novel CAR T-Cell Therapy

September 14th 2023

J. Randolph Hecht, MD, discusses the challenges researchers have faced in the development of cellular therapy for patients with solid tumors, and details how A2B530 could potentially overcome some of these obstacles.

Adagrasib Yields Durable Benefit for Patients With KRAS G12C–Mutant NSCLC

September 10th 2023

Adagrasib monotherapy provided durable efficacy for patients with KRAS G12C–mutated locally advanced or metastatic non–small cell lung cancer, according to 2-year follow-up data from the phase 1/2 KRYSTAL-1 trial.

Prognostic Model Could Help Predict Survival Outcomes for Patients With Myelofibrosis Undergoing AlloHCT

September 6th 2023

A predictive system developed using data from United States and European stem cell transplant registries was prognostic of survival in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation.

Retrospective Study Associates Alprazolam With Improved PFS in Pancreatic Cancer

September 5th 2023

The benzodiazepines lorazepam and alprazolam had differing effects on progression-free survival (PFS) outcomes among patients with pancreatic cancer, with lorazepam demonstrating an association with decreased PFS and alprazolam prolonging PFS.

BI 764532 Yields Promising Safety and Efficacy Results in DLL3+ SCLC and Neuroendocrine Carcinomas

September 5th 2023

Martin Wermke, MD, discusses why the novel agent may serve as a promising treatment option targeting DLL3.